🎯 Drug Targets

Browse 7 drug targets with druggability analysis, composite scores, and clinical context

Targets

High Druggability

0.58

Avg Score

Target Classes

Druggability Distribution

High: 0Medium: 7Low: 0Unknown: 0

Avg druggability score: 0.534

Clinical Pipeline

Approved: 3Phase III: 0Phase II: 1Phase I: 1Preclinical: 2

Total compounds: 8 · Approved: 5

Filtered by: class=signaling_protein, druggability=Medium — 7 results

C3 Complement C3 Phase 4

Signaling Protein Medium Druggability

Small molecule inhibitor of complement activation or convertase activity

G3BP1 Ras GTPase-activating protein-binding protein 1 Phase 2

Signaling Protein Medium Druggability

G3BP1 inhibitors would prevent stress granule assembly and stabilization by disrupting the interaction between G3BP1 and its binding partners, potentially reducing pathological aggregation of TDP-43 and FUS proteins. This mechanism could alleviate neurodegeneration in conditions characterized by aberrant stress granule formation and RNA metabolism dysfunction.

TNFA Tumor necrosis factor alpha Phase 4

Signaling Protein Medium Druggability

Monoclonal antibodies or soluble receptors that neutralize TNF-alpha activity

NLRP3 NACHT, LRR and PYD domains-containing protein 3 Phase 4

Signaling Protein Medium Druggability

Small molecule inhibitors targeting NLRP3 inflammasome assembly or activation

PIEZO1ANDKCNK2 PIEZO1ANDKCNK2

Signaling Protein Medium Druggability

Prioritized from 1 SciDEX hypotheses, including: Mechanosensitive Ion Channel Reprogramming

DGAT1ANDSOAT1 DGAT1ANDSOAT1

Signaling Protein Medium Druggability

Prioritized from 1 SciDEX hypotheses, including: Lipid Droplet Dynamics as Phenotype Switches

MITOCHONDRIALBIOGENESISGENES MITOCHONDRIALBIOGENESISGENES Phase 1

Signaling Protein Medium Druggability

Prioritized from 1 SciDEX hypotheses, including: Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits